Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients.

TitleReal world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients.
Publication TypeJournal Article
Year of Publication2021
AuthorsLoucera, C, Peña-Chilet, M, Esteban-Medina, M, Muñoyerro-Muñiz, D, Villegas, R, López-Miranda, J, Rodríguez-Baño, J, Túnez, I, Bouillon, R, Dopazo, J, Gomez, JManuel Que
JournalSci Rep
Volume11
Issue1
Pagination23380
Date Published2021 12 03
ISSN2045-2322
KeywordsCalcifediol; COVID-19; Female; Humans; Kaplan-Meier Estimate; Male; Retrospective Studies; Spain; Survival Analysis; Vitamin D
Abstract

COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15-30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan-Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50-0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61-0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57-0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization.

DOI10.1038/s41598-021-02701-5
Alternate JournalSci Rep
PubMed ID34862422
PubMed Central IDPMC8642445
Grant ListPAIDI2020-DOC_00350 / / Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía /
ACCI2018/29 / / Centro de Investigación Biomédica en Red sobre Enfermedades Raras /
PID2020-117979RB-I00 / / Ministerio de Ciencia e Innovación /
IMP/0019 / / Instituto de Salud Carlos III /
PI19/00033 / / Instituto de Salud Carlos III /
G999088Q / / Fundación BBVA /
813533 / / H2020 Marie Skłodowska-Curie Actions /
COVID-011-2020 / / Consejería de Salud y Familias, Junta de Andalucía /
CB16/10/00245 / / Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable /